Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin

William R. Crombleholme, Julius Schachter, Marilyn Ohm-Smith, Janis Luft, Roberta Whidden, Richard L Sweet

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

A prospective, randomized, controlled, non-blind clinical trial was conducted to compare the efficacy of monotherapy with ciprofloxacin with that of a combination of clindamycin plus gentamicin in the treatment of patients with acute pelvic inflammatory disease. Pretreatment and post-treatment cervical culture specimens were obtained for Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma urealyticum. Pretreatment and post-treatment endometrial culture specimens were obtained for those organisms plus facultative and anaerobic bacteria. Minimal inhibitory concentrations were determined on all isolates by agar dilution. Clinical resolution of infection was seen in 31 of 33 (94 percent) ciprofloxacin-treated patients compared with 34 of 35 (97 percent) clindamycin/gentamicin-treated patients. N. gonorrhoeae was eradicated in all cases and C. trachomatis in 12 of 13 cases (92 percent). Ciprofloxacin appeared less effective than clindamycin/gentamicin in eradicating bacterial-vaginosis-associated organisms from post-treatment culture specimens obtained from the endometrium. Comparable clinical response was seen with both regimens. The significance of persistent bacterial-vaginosis-associated organisms following ciprofloxacin therapy is unclear. However, since one goal of treatment of pelvic inflammatory disease should be to eliminate organisms from the upper genital tract, ciprofloxacin may not provide optimal single-agent therapy for pelvic inflammatory disease.

Original languageEnglish (US)
JournalThe American journal of medicine
Volume87
Issue number5 SUPPL. 1
StatePublished - Nov 30 1989

Fingerprint

Pelvic Inflammatory Disease
Ciprofloxacin
Clindamycin
Gentamicins
Bacterial Vaginosis
Neisseria gonorrhoeae
Chlamydia trachomatis
Therapeutics
Mycoplasma hominis
Ureaplasma urealyticum
Anaerobic Bacteria
Endometrium
Agar
Infection

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. / Crombleholme, William R.; Schachter, Julius; Ohm-Smith, Marilyn; Luft, Janis; Whidden, Roberta; Sweet, Richard L.

In: The American journal of medicine, Vol. 87, No. 5 SUPPL. 1, 30.11.1989.

Research output: Contribution to journalArticle

Crombleholme, WR, Schachter, J, Ohm-Smith, M, Luft, J, Whidden, R & Sweet, RL 1989, 'Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin', The American journal of medicine, vol. 87, no. 5 SUPPL. 1.
Crombleholme, William R. ; Schachter, Julius ; Ohm-Smith, Marilyn ; Luft, Janis ; Whidden, Roberta ; Sweet, Richard L. / Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. In: The American journal of medicine. 1989 ; Vol. 87, No. 5 SUPPL. 1.
@article{47fdc56324a1400990a621b6368fbbeb,
title = "Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin",
abstract = "A prospective, randomized, controlled, non-blind clinical trial was conducted to compare the efficacy of monotherapy with ciprofloxacin with that of a combination of clindamycin plus gentamicin in the treatment of patients with acute pelvic inflammatory disease. Pretreatment and post-treatment cervical culture specimens were obtained for Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma urealyticum. Pretreatment and post-treatment endometrial culture specimens were obtained for those organisms plus facultative and anaerobic bacteria. Minimal inhibitory concentrations were determined on all isolates by agar dilution. Clinical resolution of infection was seen in 31 of 33 (94 percent) ciprofloxacin-treated patients compared with 34 of 35 (97 percent) clindamycin/gentamicin-treated patients. N. gonorrhoeae was eradicated in all cases and C. trachomatis in 12 of 13 cases (92 percent). Ciprofloxacin appeared less effective than clindamycin/gentamicin in eradicating bacterial-vaginosis-associated organisms from post-treatment culture specimens obtained from the endometrium. Comparable clinical response was seen with both regimens. The significance of persistent bacterial-vaginosis-associated organisms following ciprofloxacin therapy is unclear. However, since one goal of treatment of pelvic inflammatory disease should be to eliminate organisms from the upper genital tract, ciprofloxacin may not provide optimal single-agent therapy for pelvic inflammatory disease.",
author = "Crombleholme, {William R.} and Julius Schachter and Marilyn Ohm-Smith and Janis Luft and Roberta Whidden and Sweet, {Richard L}",
year = "1989",
month = "11",
day = "30",
language = "English (US)",
volume = "87",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "5 SUPPL. 1",

}

TY - JOUR

T1 - Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin

AU - Crombleholme, William R.

AU - Schachter, Julius

AU - Ohm-Smith, Marilyn

AU - Luft, Janis

AU - Whidden, Roberta

AU - Sweet, Richard L

PY - 1989/11/30

Y1 - 1989/11/30

N2 - A prospective, randomized, controlled, non-blind clinical trial was conducted to compare the efficacy of monotherapy with ciprofloxacin with that of a combination of clindamycin plus gentamicin in the treatment of patients with acute pelvic inflammatory disease. Pretreatment and post-treatment cervical culture specimens were obtained for Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma urealyticum. Pretreatment and post-treatment endometrial culture specimens were obtained for those organisms plus facultative and anaerobic bacteria. Minimal inhibitory concentrations were determined on all isolates by agar dilution. Clinical resolution of infection was seen in 31 of 33 (94 percent) ciprofloxacin-treated patients compared with 34 of 35 (97 percent) clindamycin/gentamicin-treated patients. N. gonorrhoeae was eradicated in all cases and C. trachomatis in 12 of 13 cases (92 percent). Ciprofloxacin appeared less effective than clindamycin/gentamicin in eradicating bacterial-vaginosis-associated organisms from post-treatment culture specimens obtained from the endometrium. Comparable clinical response was seen with both regimens. The significance of persistent bacterial-vaginosis-associated organisms following ciprofloxacin therapy is unclear. However, since one goal of treatment of pelvic inflammatory disease should be to eliminate organisms from the upper genital tract, ciprofloxacin may not provide optimal single-agent therapy for pelvic inflammatory disease.

AB - A prospective, randomized, controlled, non-blind clinical trial was conducted to compare the efficacy of monotherapy with ciprofloxacin with that of a combination of clindamycin plus gentamicin in the treatment of patients with acute pelvic inflammatory disease. Pretreatment and post-treatment cervical culture specimens were obtained for Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma urealyticum. Pretreatment and post-treatment endometrial culture specimens were obtained for those organisms plus facultative and anaerobic bacteria. Minimal inhibitory concentrations were determined on all isolates by agar dilution. Clinical resolution of infection was seen in 31 of 33 (94 percent) ciprofloxacin-treated patients compared with 34 of 35 (97 percent) clindamycin/gentamicin-treated patients. N. gonorrhoeae was eradicated in all cases and C. trachomatis in 12 of 13 cases (92 percent). Ciprofloxacin appeared less effective than clindamycin/gentamicin in eradicating bacterial-vaginosis-associated organisms from post-treatment culture specimens obtained from the endometrium. Comparable clinical response was seen with both regimens. The significance of persistent bacterial-vaginosis-associated organisms following ciprofloxacin therapy is unclear. However, since one goal of treatment of pelvic inflammatory disease should be to eliminate organisms from the upper genital tract, ciprofloxacin may not provide optimal single-agent therapy for pelvic inflammatory disease.

UR - http://www.scopus.com/inward/record.url?scp=0024358006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024358006&partnerID=8YFLogxK

M3 - Article

C2 - 2589358

AN - SCOPUS:0024358006

VL - 87

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 5 SUPPL. 1

ER -